Biocytogen Pharmaceuticals (Beijing) Co., Ltd. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Pico Far East Holdings Ltd.

Neusoft Education Technology Co. Ltd.

China YuHua Education Corp. Ltd.

Greatview Aseptic Packaging Co., Ltd.

FSE Lifestyle Services Ltd.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

China Conch Environment Protection Holdings Ltd.

Mabpharm Ltd.

Brii Biosciences Ltd. (China)

Shimao Services Holdings Ltd.

Chen Lin Education Group Holdings Ltd.

Why is Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ?

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0.62%

Poor long term growth as Operating profit has grown by an annual rate 27.23% of over the last 5 years
High Debt Company with a Debt to Equity ratio (avg) at times

With ROE of 2.48%, it has a Very Expensive valuation with a 2.83 Price to Book Value

Over the past year, while the stock has generated a return of 282.43%, its profits have risen by 105% ; the PEG ratio of the company is 1.1

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Miscellaneous)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Biocytogen Pharmaceuticals (Beijing) Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

282.43%

3.15

80.23%

Hang Seng Hong Kong

27.36%

1.06

25.88%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

57.35%

EBIT Growth (5y)

27.23%

EBIT to Interest (avg)

-6.68

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.86

Sales to Capital Employed (avg)

26.60

Tax Ratio

12.92%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

2.08%

ROE (avg)

0.62%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

114

Industry P/E

Price to Book Value

2.83

EV to EBIT

23.86

EV to EBITDA

10.20

EV to Capital Employed

1.98

EV to Sales

3.07

PEG Ratio

1.08

Dividend Yield

ROCE (Latest)

8.31%

ROE (Latest)

2.48%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

No Trend

Bullish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Not enough Data to analyse Financial Trend

Here's what is working for Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Net Sales

Highest at HKD 618.29 MM and Grown

In each period in the last five periods

MOJO Watch

Near term sales trend is very positive

Net Sales (HKD MM)

Operating Profit

Highest at HKD 229.15 MM and Grown

In each period in the last five periods

MOJO Watch

Near term Operating Profit trend is quite positive

Operating Profit (HKD MM)

Operating Profit Margin

Highest at 37.06 % and Grown

In each period in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

At HKD 111.23 MM has Grown at 151.62%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (HKD MM)

Net Profit

At HKD 82.98 MM has Grown at 137.13%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (HKD MM)

Net Sales

At HKD 618.29 MM has Grown at 46.72%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (HKD MM)

Pre-Tax Profit

Highest at HKD 111.23 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (HKD MM)

Net Profit

Highest at HKD 82.98 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (HKD MM)

EPS

Highest at HKD 0.23

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (HKD)

Raw Material Cost

Fallen by -38.88% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Non Operating Income

Highest at HKD 0.13 MM

in the last five periods

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating income